Therapy News and Research

RSS

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Elan Corporation, plc today announced that it has enrolled the first patient in a Phase 2 clinical trial of ELND005 (Study AG201) for the treatment of agitation/aggression in patients with moderate to severe Alzheimer's disease (AD).

28 Nov 2012

Immediate behavioral intervention effective in reducing PTSD

Posttraumatic stress disorder (PTSD) is a form of learning that begins at the moment of the exposure to extremely stressful situations and that grows in impact as trauma-related memories are rehearsed and strengthened repeatedly.

28 Nov 2012

Post-prostatectomy erectile dysfunction treatment disliked

Less than half of men who initiate intracorporeal injections for post-prostatectomy erectile dysfunction are still satisfied with the treatment years later, report researchers.

27 Nov 2012

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

Amarantus BioSciences, Inc., a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

27 Nov 2012

New coverage decisions by private payers and Medicare for OAB and urge incontinence

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by private payers and Medicare.

27 Nov 2012

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis.

27 Nov 2012

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease is a very broad family of diseases. There are two main categories of liver disease:

27 Nov 2012

Buying mail-order medications may encourage patients to stick their treatments

Patients newly prescribed a cholesterol-lowering medication were more likely to pick it up from the pharmacy if they received automated phone and mail reminders, according to a study published in the Archives of Internal Medicine today.

27 Nov 2012

Routine HIV testing can reduce illness and death across Canada

Offering routine HIV testing to the general population rather than only to high-risk individuals will significantly reduce illness and death, argues Dr. Julio Montaner and coauthors in an editorial in CMAJ (Canadian Medical Association Journal).

27 Nov 2012

Children with asthma benefit from cognitive behaviour therapy programme

Researchers have found that a programme of cognitive behaviour therapy delivered by nurses to children who had asthma and anxiety improved the children's quality of life scores and reduced the risk of escalation of treatment.

27 Nov 2012

Azathioprine exposure concerns raised for SLE mothers

Researchers have raised the possibility of an increased risk for developmental delay in the children of mothers who used azathioprine for systemic lupus erythematosus during pregnancy.

26 Nov 2012

Breast cancer overdiagnosis concerns for USA

Around a third of screening-detected breast cancers in US women in 2008 may have been overdiagnosed, suggests research published in The New England Journal of Medicine.

26 Nov 2012

Tivantinib holds personalized therapy promise in HCC

Tivantinib is an effective second-line therapy for hepatocellular carcinoma patients whose tumors exhibit high MET receptor tyrosine kinase expression, indicate phase II study results.

26 Nov 2012

New therapeutic technique to repair and rebuild muscle for degenerative muscle disorders

A study published today in BioMed Central's open access journal Skeletal Muscle reports of a new therapeutic technique to repair and rebuild muscle for sufferers of degenerative muscle disorders. The therapy brings together two existing techniques for muscle repair - cell transplantation and tissue engineering - specifically, mesoangioblast stem cells delivered via a hydrogel cell-carrier matrix.

26 Nov 2012

First evidence of blood vessel dysfunction found in healthy young people with cystic fibrosis

The first evidence of blood vessel dysfunction has been found in a small cohort of generally healthy young people with cystic fibrosis, researchers report.

26 Nov 2012

Applied relaxation can help women with menopausal troubles

Women who have undergone group therapy and learned to relax have reduced their menopausal troubles by half, according to results of a study at Link-ping University and Link-ping University Hospital in Sweden. Seven out of every ten women undergoing menopause have at some point experienced problems with hot flushes and sweating.

26 Nov 2012

Overexpressed enzyme contributes to development of preeclampsia

Preeclampsia is a serious complication of pregnancy and the major cause of death for both mother and child in Europe and the U.S. It affects about one in 20 pregnancies. The main symptoms are high blood pressure and protein in the urine.

26 Nov 2012

Elsevier announces launch of Leukemia Research Reports journal

Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new open access, online journal, Leukemia Research Reports.

26 Nov 2012

Avermectin family of drugs shows promise against TB

A well-established family of drugs used to treat parasitic diseases is showing surprising potential as a therapy for tuberculosis (TB), according to new research from University of British Columbia microbiologists.

26 Nov 2012

BSD-2000 Hyperthermia System purchased by Cancer Treatment Centers of America

BSD Medical Corporation, a leading provider of medical systems that utilize targeted heat therapy to treat cancer, announced today that the Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (WRMC), located in Goodyear, Arizona, has purchased a BSD-2000 Hyperthermia System (BSD-2000).

26 Nov 2012